Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upfront SRT plus ivonescimab-chemotherapy versus upfront ivonescimab-chemotherapy for active asymptomatic brain metastases from NSCLC
2025-522985-60-00Phase 2Authorised
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Oct 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of ivonescimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Intracranial progression-free survival. Planned start Oct 2026; status: authorised.
02
Drugs
ivonescimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-522985-60-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522985-60-00.